FT-1518

FT-1518 is a potent, orally bioavailable, small molecule inhibitor of the mechanistic target of rapamycin (mTOR) complexes 1 and 2 (mTORC1 and mTORC2). Developed by FTG (Felix T. Garzon and colleagues), it is designed to selectively target the mTOR kinase while avoiding inhibition of the related PI3K and DNA-PK pathways. By blocking both mTOR complexes, FT-1518 aims to overcome the limitations of first-generation mTOR inhibitors (rapalogs), which primarily target mTORC1 and can lead to compensatory activation of Akt via mTORC2. Preclinical studies have demonstrated that FT-1518 exhibits dose-dependent tumor growth inhibition in multiple solid tumor xenografts and possesses a favorable toxicology profile, making it a candidate for cancer therapy, potentially in combination with other agents due to its strong p450 profile.